Europe Startup Funding Rounds
Startups raising capital across Europe. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 242 Sep 30 – Oct 29, 2026
- Disclosed funding
- $4.2B 123 disclosed amounts
- Median round
- $6.5M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| E ENOSIS develops biological methanation equipment for renewable-gas production. | Undisclosed | Selected for grant agreement preparationUndisclosed | Climate tech | France | Investors | |
| C ChainCraftCompany profile ChainCraft produces circular fatty acids from organic residues for chemical and agri-food applications. ChainCraft produces circular fatty acids from organic residues for chemical and agri-food applications. | Undisclosed | Selected for grant agreement preparationUndisclosed | Climate tech | Netherlands | Investors | |
| tm traceless materialsCompany profile traceless materials develops natural-polymer materials from agricultural residues for packaging and industrial manufacturing. traceless materials develops natural-polymer materials from agricultural residues for packaging and industrial manufacturing. | Undisclosed | Selected for grant agreement preparationUndisclosed | Climate tech | Germany | Investors | |
| M MicrobioticaCompany profile Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment. Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment. | £36M | Series C first closeSeries C+ | Biotech | United Kingdom | Investors | |
| UH Unravel HealthCompany profile Unravel Health develops saliva-based hormone monitoring for use at home. Unravel Health develops saliva-based hormone monitoring for use at home. | >£2M | First closeUndisclosed | Healthtech | United Kingdom | Investors | |
OMass TherapeuticsCompany profile OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings. OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings. | $310M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| D DougsCompany profile A French accounting firm combining its own software with accounting, tax and legal services for small businesses. A French accounting firm combining its own software with accounting, tax and legal services for small businesses. | €50M | Growth investmentGrowth | Business services | France | Investors | |
| H HoloCompany profile Holo helps small businesses plan marketing campaigns, create content and publish it across connected channels. Holo helps small businesses plan marketing campaigns, create content and publish it across connected channels. | €5M | Seed | Enterprise software | Lithuania | Investors | |
GasLabCompany profile GasLab is developing a generative music platform that links AI-created tracks to participating artists and rights holders so they can share in the revenue. GasLab is developing a generative music platform that links AI-created tracks to participating artists and rights holders so they can share in the revenue. | ~$1M | Pre-seed | Media & gaming | Netherlands | Investors | |
| C ConstrikCompany profile AI estimating platform helping construction firms review project documents, costs and bid risks. AI estimating platform helping construction firms review project documents, costs and bid risks. | €350K | Pre-seed | Enterprise software | Spain | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Sep 30, 2026
- 1EU Innovation Fund
Epyr, Reverion, H2SITE
17rounds0led - 2NVIDIA
Riverlane, Foresight, Hiverge
7rounds0led - 3Creandum
Atlas Bio, Machenta, 22one
6rounds2led - 4Portfolio Ventures
Marrow, IMMIX, Cleavr
4rounds0led - 5Innovate UK
Emerald, Go Eve, Affinity Labs
4rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.